Pacira Contract

Quote







David M. Stack
Salary $462,000
Bonus $231,000
Total Annual Compensation $693,000
Stock Options*
All Other Compensation $2,879
Exercisable Options 409,021
Unexercisable Options 541,100
Total Number of Options 950,121
Total Compensation*
Total Annual Cash Compensation $695,879
Total Short Term Compensation $693,000
Other Long Term Compensation $2,879
Total Calculated Compensation $3,173,91
 


















Those areas are only doing well because of the Ortho distributor reps. Those guys are the ones driving the business and getting the product in the hospitals. The clinical specialist don't know how to talk to surgeons and the Pacira sales reps are idiots. Now that Ortho is blowing up they are pushing out the distributor reps. Seems like a brilliant strategy.
 



So the sales people are idiots you say. Most of us have had a long highly successful career in the medical field.

If is any failure it is your lack of understanding of this market and your own analytical skills

Go back underneath your rock!
 






A large majority of the reps are not the best and brightest. A lot have really just ridden the sales pushed by surgeon word of mouth and not actually driven the numbers through their own actions. If Pacira fire all the reps tomorrow I would be willing to be the sales numbers would stay close to the same or may continue to grow.
 



You are an idiot with no clue on what it takes to work it through the system. Your comments show your ignorance and lack of understanding of how the product works and what it takes to make it available for a surgeon. Enjoy your idiocy!
 






Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter

PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 25, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the receipt of a Warning Letter (attached for reference) from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) referencing certain promotional materials on EXPAREL® (bupivacaine liposome injectable suspension).
 



Anonymous said:
Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter

PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 25, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the receipt of a Warning Letter (attached for reference) from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) referencing certain promotional materials on EXPAREL® (bupivacaine liposome injectable suspension).
Click to expand...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pacira Pharmaceuticals, Inc. - PCRX

NEW YORK, Sept. 25, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company") (PCRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.

The investigation concerns whether Pacira and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On September 25, 2014, the Company announced that it received a Warning Letter from the U.S. Food and Drug Administration's ("FDA") Office of Prescription Drug Promotion referencing certain promotional materials for EXPAREL® (bupivacaine liposome injectable suspension), an injectable drug that numbs post-surgical pain.

In the letter, the FDA said Pacira promotes its drug EXPAREL as being able to work for up to 72 hours when it has only been approved for 24-hour pain relief. "These claims overstate Exparel's efficacy and are misleading," the FDA said in the letter.

On this news, shares of Pacira fell $4.70 per share to $101.58, or more than 4.42%, in intraday trading on September 25, 2014.

The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
 



Ha Ha Ha ha ha ha ha ha ha

Pacira Receives Subpoena from the U.S. Department of Justice

* Reuters is not responsible for the content in this press release.

Pacira Receives Subpoena from the U.S. Department of Justice

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it received a subpoena from the U.S. Department of Justice, U.S. Attorney’s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to the product EXPAREL® (bupivacaine liposome injectable suspension). Pacira intends to cooperate with the government’s investigation.


Anonymous said:
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pacira Pharmaceuticals, Inc. - PCRX

NEW YORK, Sept. 25, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company") (PCRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.

The investigation concerns whether Pacira and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On September 25, 2014, the Company announced that it received a Warning Letter from the U.S. Food and Drug Administration's ("FDA") Office of Prescription Drug Promotion referencing certain promotional materials for EXPAREL® (bupivacaine liposome injectable suspension), an injectable drug that numbs post-surgical pain.

In the letter, the FDA said Pacira promotes its drug EXPAREL as being able to work for up to 72 hours when it has only been approved for 24-hour pain relief. "These claims overstate Exparel's efficacy and are misleading," the FDA said in the letter.

On this news, shares of Pacira fell $4.70 per share to $101.58, or more than 4.42%, in intraday trading on September 25, 2014.

The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
Click to expand...
 
Last edited by a moderator:



Top Bottom
Back
Quote